The G7 OsseoTi shell received the CE mark and FDA clearance in November and December 2014, respectively. The first clinical use of the technology also took place in December 2014.
The G7 OsseoTi shell is used in conjunction with Biomet’s G7 Acetabular System, a multi-bearing acetabular platform designed for primary and revision hip arthroplasty.
More articles on devices:
DePuy Synthes buys Olive Medical — 5 things to know
K2M CFO Gregory Cole sells 40k shares — 5 things to know
Still on edge with Zimmer-Biomet acquisition — 5 key points from updated proposal
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
